Understanding of sarcopenia: from definition to therapeutic strategies

被引:0
|
作者
Jee Won Kim
Ryuni Kim
Hyerim Choi
Sang-Jin Lee
Gyu-Un Bae
机构
[1] Sookmyung Women’s University,Drug Information Research Institute, College of Pharmacy
[2] AniMusCure Inc.,Research Institute of Aging
来源
关键词
Sarcopenia; Aging; Skeletal muscle; Satellite cell; Protein turnover;
D O I
暂无
中图分类号
学科分类号
摘要
Sarcopenia refers to the gradual loss of skeletal muscle mass and function along with aging and is a social burden due to growing healthcare cost associated with a super-aging society. Therefore, researchers have established guidelines and tests to diagnose sarcopenia. Several studies have been conducted actively to reveal the cause of sarcopenia and find an economic therapy to improve the quality of life in elderly individuals. Sarcopenia is caused by multiple factors such as reduced regenerative capacity, imbalance in protein turnover, alteration of fat and fibrotic composition in muscle, increased reactive oxygen species, dysfunction of mitochondria and increased inflammation. Based on these mechanisms, nonpharmacological and pharmacological strategies have been developed to prevent and treat sarcopenia. Although several studies are currently in progress, no treatment is available yet. This review presents the definition of sarcopenia and summarizes recent understanding on the detailed mechanisms, diagnostic criteria, and strategies for prevention and treatment.
引用
收藏
页码:876 / 889
页数:13
相关论文
共 50 条
  • [21] Towards a definition of sarcopenia - results from epidemiologic studies
    Visser, M.
    JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (08): : 713 - 716
  • [22] Potential novel therapeutic strategies from understanding adipocyte transdifferentiation mechanisms
    Sartini, Loris
    Frontini, Andrea
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (02) : 143 - 152
  • [23] The Conceptual Definition of Sarcopenia: Delphi Consensus from the Global Leadership Initiative in Sarcopenia (GLIS)
    Kirk, Ben
    Cawthon, Peggy M.
    Arai, Hidenori
    Avila-Funes, Jose A.
    Barazzoni, Rocco
    Bhasin, Shalender
    Binder, Ellen F.
    Bruyere, Olivier
    Cederholm, Tommy
    Chen, Liang-Kung
    Cooper, Cyrus
    Duque, Gustavo
    Fielding, Roger A.
    Guralnik, Jack
    Kiel, Douglas P.
    Landi, Francesco
    Reginster, Jean-Yves
    Sayer, Avan A.
    Visser, Marjolein
    von Haehling, Stephan
    Woo, Jean
    Cruz-Jentoft, Alfonso J.
    AGE AND AGEING, 2024, 53 (03)
  • [24] Molecular mechanisms and therapeutic strategies of gut microbiota modulation in Sarcopenia (Review)
    Yuan, Chanqi
    ONCOLOGY LETTERS, 2025, 29 (03)
  • [25] Emerging Therapeutic Strategies in Sarcopenia: An Updated Review on Pathogenesis and Treatment Advances
    Najm, Alfred
    Niculescu, Adelina-Gabriela
    Grumezescu, Alexandru Mihai
    Beuran, Mircea
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (08)
  • [26] Therapeutic strategies to modulate gut microbial health: Approaches for sarcopenia management
    Das, Shreya
    Preethi, B.
    Kushwaha, Sapana
    Shrivastava, Richa
    HISTOLOGY AND HISTOPATHOLOGY, 2024, 39 (11) : 1395 - 1425
  • [27] DEFINITION, PATHOPHYSIOLOGY, AND MANAGEMENT OF SARCOPENIA
    Fielding, R.
    OSTEOPOROSIS INTERNATIONAL, 2014, 25 : S103 - S103
  • [28] TOWARDS AN OPERATIONAL DEFINITION OF SARCOPENIA
    Kanis, J. A.
    Harvey, N.
    Johansson, H.
    McCloskey, E. V.
    Oden, A.
    OSTEOPOROSIS INTERNATIONAL, 2016, 27 : S688 - S689
  • [29] Contribution of therapeutic strategies for understanding the Tourette syndrome
    Mallet, L.
    Burguiere, E.
    Worbe, Y.
    Hartmann, A.
    EUROPEAN PSYCHIATRY, 2015, 30 (08) : S19 - S20
  • [30] WHAT IS NEW IN THE DEFINITION OF SARCOPENIA?
    Cruz-Jentoft, A. J.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S197 - S197